Next 10 |
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immun...
2024-05-14 11:52:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips MiNK Therapeutics (NASDAQ: INKT ) just reported results for the first quarter of 2024. MiNK Therapeutics reported earnings per share of -11 cents. This was above the analy...
2024-05-14 11:07:01 ET MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Conference Call May 14, 2024, 08:30 AM ET Company Participants Zack Armen - Head, Investor Relations Jennifer Buell - President and Chief Executive Officer Marc Van Dijk - Chief Scientific Off...
2024-05-14 10:25:35 ET More on MiNK Therapeutics MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on MiNK Therapeutics Historical earnings data for MiNK Therapeutics Financial information for MiNK Therapeutic...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS) AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models...
Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKT GKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDA...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other imm...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 96.2% to $0.0785 on volume of 428,216,483 shares Mobile Global Esports Inc. (MGAM) rose 77.8% to $0.216 on volume of 139,335,972 shares PROSHARES TRUST (SQQQ) fell 1.2% to $10.61 on volume of 128,866...
2024-04-08 12:24:13 ET Gainers: Auddia AUUD +231% . Etao International Co Ltd. ( ETAO ) +143% . Longeveron LGVN +56% . Adlai Nortye Ltd. ( ANL ) +53% . U Power Ltd UCAR +33% . MSP Recovery LIFW +29% . Techprecision Corp TPCS +2...
News, Short Squeeze, Breakout and More Instantly...
MiNK Therapeutics Inc. Company Name:
INKT Stock Symbol:
NASDAQ Market:
MiNK Therapeutics Inc. Website:
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immun...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS) AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models...